PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.68M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
110.84%
Some net income increase while VET is negative at -1501.41%. John Neff would see a short-term edge over the struggling competitor.
15.43%
Less D&A growth vs. VET's 449.28%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
240.46%
Some yoy growth while VET is negative at -160.67%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
16.67%
SBC growth well above VET's 23.72%. Michael Burry would flag major dilution risk vs. competitor’s approach.
163.53%
Well above VET's 100.47% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
133.37%
AR growth of 133.37% while VET is zero at 0.00%. Bruce Berkowitz would see a mild difference in credit approach that could matter for cash flow.
-100.00%
Negative yoy inventory while VET is 0.00%. Joel Greenblatt would see a near-term cash advantage if top-line doesn't suffer.
-100.00%
Negative yoy AP while VET is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
119.78%
Growth well above VET's 100.47%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
8632.93%
Some yoy increase while VET is negative at -177.97%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
44.87%
Operating cash flow growth below 50% of VET's 190.31%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
24.89%
Lower CapEx growth vs. VET's 97.46%, potentially boosting near-term free cash. David Dodd would confirm no missed expansions that competitor might exploit.
234.68%
Acquisition growth of 234.68% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-696.59%
We reduce yoy other investing while VET is 947.76%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
15.20%
Investing outflow well above VET's 21.99%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-15084.57%
Both yoy lines negative, with VET at -802.25%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
-17.78%
Both yoy lines negative, with VET at -146.77%. Martin Whitman would see an overall reduced environment for buybacks in the niche or cyclical factor driving capital usage.